Department of Pediatrics, Harbor-UCLA Medical Center, Torrance, California 90509
![]() |
ABSTRACT |
---|
![]() ![]() ![]() ![]() ![]() ![]() ![]() |
---|
Among the many tracer methods to indirectly estimate gluconeogenesis in humans, the [U-13C6]glucose method as proposed by Tayek and Katz (Am J Physiol Endocrinol Metab 270: E709-E717, 1996; Am J Physiol Endocrinol Metab 272: E476-E484, 1997) has the advantage of being able to simultaneously estimate hepatic glucose output and fractional gluconeogenesis. However, Landau et al. (Landau BR, J Wahren, K Ekberg, SF Previs, D Yang, and H Brunengraber. Am J Physiol Endocrinol Metab 274: E954-E961, 1998) have shown that this method underestimates the rate of gluconeogenesis. The underestimation has been attributed to tracer dilution by other three-carbon substrates and the lack of isotopic steady state. Using a computer simulation of [U-13C6]glucose infusion, we demonstrate that the lack of isotope equilibrium in both the lactate and glucose compartments contributes substantially to the underestimation of gluconeogenesis. [U-13C6]glucose experiments were performed with the addition of a primed constant infusion of [U-13C3]lactate and the delay in M3 glucose equilibrium estimated from the isotopic steady-state value determined by modeling M3 glucose to a single-exponential fit. We found that, even with the addition of [U-13C3]lactate infusion, the M3 glucose enrichment of the last timed sample was ~20% less than the isotopic steady-state value. Thus the lack of isotopic equilibrium of the glucose compartment potentially accounts for 20% of the underestimation of gluconeogenesis. The underestimation of gluconeogenesis using [U-13C6]glucose without the additional infusion of [U-13C3]lactate in previous publications is expected to be even greater because of the lack of isotope equilibrium in both the lactate and glucose compartments. These findings are consistent with the results from our computer simulation.
mathematical modeling; mass isotopomer distribution analysis, stable isotopes
![]() |
INTRODUCTION |
---|
![]() ![]() ![]() ![]() ![]() ![]() ![]() |
---|
THE RECOGNITION THAT [U-13c6]glucose has the property of being both a "nonrecyclable" and a "recyclable" tracer (9) has led Tayek and Katz (15, 16) to propose a method of estimating gluconeogenesis by the use of [U-13C6]glucose. During an infusion of [U-13C6]glucose (glucose labeled in all six positions, M6 glucose), glycolysis leads to the production of lactate labeled in all three carbon positions (m3 lactate). When 13C carbon atoms are recycled in gluconeogenesis, glucose molecules with 1, 2, or 3 13C substitutions (M1, M2, and M3 glucose) are produced. The appearance of mass isotopomers M1, M2, and M3 of glucose provides a measure of the rate of gluconeogenesis. Because the chance of two labeled triose phosphates combining to form glucose is negligible, M6 glucose behaves as a nonrecyclable tracer, and the steady-state enrichment of M6 glucose in plasma allows the determination of the hepatic glucose production rate. Thus the [U-13C6]glucose method has the advantage of being able to estimate simultaneously hepatic glucose output and fractional gluconeogenesis from the analysis of mass isotopomers in glucose. However, Landau et al. (7) have shown that, when [U-13C6]glucose is administered as a primed constant infusion, this method grossly underestimates the rate of gluconeogenesis. This underestimation could be attributed to dilution by other unlabeled gluconeogenic substrates and/or the lack of label steady state in m3 lactate and M3 glucose by the end of the study period. In the absence of experimental data, the magnitude of underestimation of gluconeogenesis by the [U-13C6]glucose method attributable to each of these sources of error remains controversial (2, 5, 11, 12).
Because the 13C label from M6 glucose is recycled through an intermediate compartment, namely lactate, before gluconeogenesis, the precursor-product relationship of labeled substrate from M6 glucose to newly synthesized glucose is complex. A basic principle of precursor-product relationship dictates that the isotope in each precursor pool must be in isotopic steady state before the subsequent pool can reach its plateau enrichment. Therefore, the time to reach isotopic steady state for M3 glucose (new glucose) can be significantly delayed, depending on the time to reach isotopic steady state of its precursors, namely m3 lactate and M6 glucose. Potentially, the lack of isotope equilibrium may contribute significantly to the underestimation of gluconeogenesis.
The relative importance of various factors contributing to the problems of accurately measuring gluconeogenesis is difficult to evaluate in clinical studies. It is costly and impractical to perform a large number of experiments using different infusion protocols to demonstrate the effects of many variables on isotope equilibrium (M6 glucose, m3 lactate, and M3 glucose). To obviate these difficulties, we have designed a computer model to simulate glucose and lactate tracer kinetics to examine the effects of tracer infusion on isotopic equilibrium of m3 lactate and M3 glucose and to test the effects of different assumptions of tricarboxylic acid (TCA) cycle dilution on the calculation of gluconeogenesis. Clinical experiments were performed using the same assumptions of tracer dilution from previous indirect methods to measure gluconeogenesis, and the plateau value was estimated using curve fitting with SAAM. The delay in isotopic equilibrium of the precursor pools (namely m3 lactate and M6 glucose) was minimized using a primed constant infusion of L-[U-13C3]lactate and D-[U-13C6]glucose. The expected steady-state enrichment of M3 glucose was determined from the asymptote of the appearance curve fitted to a single exponential model using SAAM. With the assumption that our model holds for M3 glucose appearance, any underestimation due to lack of isotopic equilibrium of the newly produced labeled glucose can be determined from the difference between the asymptote and the observed value of M3 glucose.
![]() |
METHODS |
---|
![]() ![]() ![]() ![]() ![]() ![]() ![]() |
---|
Computer Simulation of Glucose and Lactate Tracer Kinetics
The model.
The system through which [U-13C6]glucose
carbon is recycled is inherently complex. As indicated in the model of
Landau et al. (7) for the mass isotopomer distribution in
glucose and lactate, there are three basic substrate pools, each of
which has its own pool size and substrate turnover rate. A very large
number of experiments are necessary to evaluate the effect of each
model parameter on tracer kinetics. For this reason, we have chosen to
use computer simulation to examine these effects on tracer kinetics.
Computer simulation allows us to examine the individual effect by
changing model parameters one at a time. We have modified the model of
Landau et al., which simulates the mass isotopomer distribution in
glucose and lactate at steady state during a
[U-13C6]glucose infusion to allow the
generation of time-dependent tracer kinetics (Fig.
1). This is accomplished by 1)
defining small steps of hepatic glucose output indicated by
gluconeogenesis (D) and glycogenolysis (E), 2) manipulating
the substrate turnover rate by changing either the glucose or lactate
pool size, and 3) modeling of loss of lactate carbon via the
TCA cycle. Fractional gluconeogenesis is simulated by the ratio
D/(D + E) and lactate dilution by the ratio A/(A + B). The model can simulate different combinations of primed and
unprimed infusion of glucose and lactate by setting the
[U-13C6]glucose priming dose (GP),
[U-13C6]glucose infusion rate (GI),
[U-13C3]lactate priming dose (LP), and
[U-13C3]lactate infusion rate (LI). As an
example, a set of parameters for the simulation of a primed constant
infusion of [U-13C6]glucose is shown in Table
1. The parameters are set to simulate the
conditions of a typical [U-13C6]glucose
infusion. The [U-13C6]glucose infusion rate
is set to 5% of the glucose production rate. The turnover rate and the
pool size of glucose and lactate are comparable. The gluconeogenesis
rate is set to 50%.
|
|
Effect of tracer priming on tracer kinetics.
The tracer appearance curves of M6 and M3 glucose may follow a
single-exponential equation or multiexponential equation,
depending on the site of infusion and priming in a
multicompartment system. To illustrate the effects of priming doses of
[U-13C6]glucose and/or
[U-13C3]lactate on the tracer kinetics of M6
and M3 of glucose and m3 of lactate, we focused on the simplified
condition that m3 of lactate can be converted only to m3
phosphoenolpyruvate (PEP). The simulations were performed
with no prime (Fig. 2A),
[U-13C6]glucose prime only (Fig.
2B), and [U-13C6]glucose and
[U-13C3]lactate prime (Fig. 2C).
The SAAM curve-fitting program is used to test whether the M6 glucose
(M6), m3 lactate (m3), and M3 glucose (M3) tracer appearance from the
simulation fits that of a single exponential or multiexponential
equation. Each appearance curve is initially modeled with the
single-exponential Eq. 1
![]() |
(1) |
|
![]() |
(2) |
![]() |
(3) |
![]() |
Effect of tracer conversion.
The effect of the loss of 13C during the conversion of
lactate to PEP is simulated by setting the conversion of m3 lactate to m3, m2, and m1 PEP with a ratio of 0.3:0.3:0.4, assuming no loss of
labeled molecules. That is, 100% of m3 lactate is converted to labeled
PEP, with the distribution of mass isotopomers in PEP being
0.3:0.3:0.4, and there is no further loss of m2 and m1 lactate. The
choice of m3, m2, and m1 and their ratio is arbitrary. Under the
assumption of "no loss of labeled molecules," the simulation is
applicable to the most general case such that m3, m2, and m1 may as
well be m, m
, and m
and their ratio
x:y:z, as long as m
, m
, and m
cannot become m0 through the TCA
cycle.1
Clinical Studies: Subjects and Methods
Protocols.
To demonstrate the lack of isotope equilibrium, gluconeogenesis was
studied in four healthy volunteers in the General Clinical Research
Center (GCRC) at Harbor-UCLA Medical Center by use of a primed constant
infusion of glucose and lactate. The project was approved by the
Institutional Review Board. Subjects consisted of two women and
two men. Table 2 shows the subject
characteristics for each subject. All subjects were instructed to
maintain a diet with 200 g of carbohydrates per day for the 3 days
preceding the study. Subjects were also instructed not to eat or drink
anything after midnight the night before the study. Subjects arrived at the GCRC ~8:00 AM on the day of the study. All studies were initiated between 9:00 and 10:00 AM after an overnight fast (
9 h) and after informed consent was obtained. Subjects had cannulation of a deep vein
in each arm, one for blood sampling and the other for infusion of
tracers. After baseline blood samples were obtained, a priming dose of
[U-13C6]glucose (0.5 g) and of
[U-13C3]lactate (0.25 g) was infused over the
first 15 min. The priming doses were followed by a constant infusion of
labeled glucose (0.5 g/h) and labeled lactate (0.25 g/h) over the
remainder of the 3-h study. Blood sampling was performed at 20-min
intervals. Samples were placed on ice immediately and processed to
obtain the plasma fractions, which were stored at
20°C until gas
chromatography-mass spectrometry (GC-MS) analyses. Two subjects
returned for a second study. The second study was identical to the
first study, except that the rate of labeled lactate infusion was
increased (0.5 g prime and 0.5 g/h) and both the labeled glucose and
labeled lactate infusions were extended to 4 h. The high-dose
lactate infusion study was performed to determine whether we could
further improve estimations of M3 glucose plateau enrichment.
|
Materials. D-[U-13C6]glucose (99% enriched) and L-[U-13C3]lactate (99% enriched) were purchased from Isotec (Miamisburg, OH). The isotopes were dissolved in isotonic saline and tested to be sterile and pyrogen free by the research pharmacist of the Harbor-UCLA Research and Education Institute.
Laboratory analyses. Plasma glucose, insulin, and lactate were measured in all samples from an individual study in duplicate in the same assay. Plasma glucose was measured using the hexokinase method with an Abbott autoanalyzer (1). Plasma insulin was measured by sensitive radioimmunoassay (18). Plasma lactate was collected in perchloric acid and measured using a fluorescence polarization immunoassay.
Sample preparation and GC-MS analyses. Plasma samples (200 µl) were deproteinized with 6% perchloric acid. The supernatant was neutralized and then passed through a set of tandem columns of Dowex 50 and Dowex 1 to isolate glucose and lactate. These fractions were dried by blowing air and were used for subsequent GC-MS analyses. Mass spectral data were obtained on the HP5973 mass spectrometer connected to an HP6890 gas chromatograph. GC conditions: inlet 230°C, transfer line 280°C, MS source 230°C, and MS Quad 150°C. An HP-5 capillary column (30 m length, 250 µm diameter, and 0.25 µm film thickness) was used for glucose and lactate analysis. Glucose was converted to its aldonitrile pentaacetate derivative for GC-MS analysis according to a modification of the method of Szafranek et al. (14). Ions around mass-to-charge ratio (m/z) 328 were monitored under positive chemical ionization condition to give the isotopomeric distribution of glucose. Lactic acid was converted to its n-propylamide-heptafluorobutyric ester for GC-MS analysis according to the method of Tserng et al. (17). The mass spectrum of n-propylamide heptafluorobutyrate of lactate has two major ion clusters around m/z 328 and 241, representing fragments containing C1-C3 and C2-C3 of lactate. The molecular ion m/z 328 was used in the quantitative analysis of lactate and mass isotopomer determination. Mass isotopomer distribution was determined from spectral data by use of a matrix method, which corrects for the natural abundance of 13C (3).
Calculations
Gluconeogenesis.
Because we infused [U-13C3]lactate together
with [U-13C6]glucose, the calculation
followed the traditional approach of determining gluconeogenesis from
labeled lactate infusion. Total glucose production (Ra) was
first calculated using Eq. 4
![]() |
(4) |
![]() |
(5) |
![]() |
(6) |
![]() |
(7) |
Mathematical modeling of clinical studies. To assess the impact of primed constant infusion of lactate and glucose, we applied the curve-fitting program on measured M3 glucose enrichment of each time point from the same subject. The multicompartmental model of Landau et al. (7) predicts that the appearance of M3 glucose follows that of a multiexponential equation. The appearance of M3 glucose can be fitted to a single exponential only when both glucose and lactate pools are primed with the respective tracers. The purpose of modeling the clinical data is to determine whether appearance of plasma M3 glucose enrichment fits a single exponential model. A fit would provide evidence that the tracer priming is adequate and that the in vivo system behaves like the model of Landau et al. Modeling of clinical data is used to determine whether the M3 glucose appearance curve could be predicted using a single exponential equation and, if so, what the M3 enrichment is at the true plateau (13). The Simulation Application for the Analysis of Models (SAAM) program for exponential fit provides the estimation of AIC as a measure of the goodness of fit. The ratio of the M3 glucose plateau enrichment observed at the end of the study to the calculated M3 glucose plateau enrichment gives the degree of underestimation of plateau enrichment. The observed gluconeogenic fraction can be corrected to give a better estimate of gluconeogenic fraction by use of this factor.
![]() |
RESULTS |
---|
![]() ![]() ![]() ![]() ![]() ![]() ![]() |
---|
Computer Simulation of Glucose and Lactate Tracer Kinetics
Effect of tracer priming.
When there is no priming of [U-13C6]glucose
and [U-13C3]lactate (Fig. 2A), the
enrichment of M6 glucose exhibits the characteristics of a single
exponential curve having a half-life of ~35 relative time units. The
curves for m3 lactate and M3 glucose are better characterized by curves
of two or three exponential terms, consistent with the tracer kinetics
of a multicompartmental system. The results of SAAM analysis are shown
in Table 3. In most clinical experiments, four half-lives for M6 glucose is conventionally used as the optimal time to reach equilibrium. It is obvious that, even if M6 glucose is at
equilibrium, neither m3 lactate nor M3 glucose achieves steady state
without priming (Fig. 2).
|
|
Effect of tracer conversion.
The effect of the loss of 13C during the conversion of
lactate to PEP was simulated by setting the conversion of m3 lactate to
m3, m2, and m1 PEP with a ratio of 0.3:0.3:0.4, with the assumption of
no loss of labeled molecules. The appearance curves of m3, m2, and m1
lactate are clearly different from one another. These differences are
reflected in the isotopomer enrichment of M3, M2, and M1 glucose over
time (Fig. 4A). The curves for
enrichment of M6 glucose, new glucose (M3 + M2 + M1), and
labeled lactate (m3 + m2 + m1) (Fig. 4B) resemble
those shown in Fig. 2C.
|
Clinical Studies
The plasma glucose, insulin, and lactate results are shown in Table 2. For the initial study, mean basal plasma glucose was 90.8 ± 7.2 mg/dl, mean basal plasma insulin was 9.4 ± 2.6 µU/ml, and mean basal plasma lactate concentration was 1.1 ± 0.4 mmol/l. At the end of the study, these values were unchanged.Mass isotopomers of glucose and lactate.
With the [U-13C3]lactate infusion, we were
able to achieve an M3 enrichment of ~1% with a concurrent M6
enrichment of ~5% at 180 min. The precision of M3 at levels below
0.5% was poor, and the coefficient of variation ranged from 10 to
50%. The lactate enrichment (m3 + m2 + m1, the sum of
labeled molecules expressed as a fraction of the lactate molecules)
curve is shown in Fig. 5. It is clear
that, despite priming of the lactate pool, we did not achieve constant
m3 lactate enrichment. However, the degree of priming was sufficient to
permit a good fit of the M3 glucose appearance to that of a single
exponential, as discussed in SAAM model.
|
Gluconeogenesis.
In Table 4, the results of total glucose
production, gluconeogenesis, and the gluconeogenic fraction of total
glucose production for each subject are shown. In the low-dose lactate
study, the mean total fasting glucose output, Ra, was
1.94 ± 0.23 mg · kg1 · min
1. The
gluconeogenic fraction, based on the measured plateau, was 31.07 ± 7.88%. In the two subjects with a second study, the total glucose
output was 1.56 and 1.98 mg · kg
1 · min
1. The
fractional rates of gluconeogenesis based on measured plateau values
were 38.83 and 31.68%.
|
SAAM model.
The SAAM models of M3 glucose plasma enrichment for each study are
shown in Fig. 6. The SAAM exponential
model for M3 glucose enrichment is shown by the dashed curve. For each
subject, the measured plateau enrichment, the calculated plateau
enrichment, and the correction factor are shown. The results of SAAM
modeling are summarized in Table 5. Each
subject had a good fit to a single-exponential model for M3 glucose
enrichment with the use of SAAM according to the AIC criteria. The
negative AIC indicates a good fit of the experimental data to the model
in each study. The flux constant (a1) and the calculated M3
glucose plateau enrichment (A0) with their respective
confidence intervals are also shown in Table 5.
|
|
Correction for underestimation of plateau.
The calculated M3 glucose plateau enrichments based on the SAAM model
were used to determine the amount of underestimation of the measured
"plateau" enrichment. The results are summarized in Table
6. The measured plateau enrichment
(column 2) ranged from 0.46 to 1.27%. The underestimation
of the mathematically predicted value by the measured plateau is shown
in column 4. The correction factor for the low-dose lactate
infusion study ranged from 0.73 to 0.88. With the high-dose lactate
infusion study, the underestimation appears to be less. The calculated plateau enrichment (column 5) ranged from 0.52 to 1.47%.
The measured M3 glucose fraction was only 81.0 ± 7.9% of the
corrected plateau value. Thus the corrected fractional gluconeogenesis
was 39.1 ± 12.3%. In the two subjects with a second study, the
measured M3 glucose enrichment was 86.1 and 109.3% of the calculated
plateau by the end of the primed infusion. Thus the corrected rates of gluconeogenesis were 45.1 and 29.0%. In the six separate studies, the
average gluconeogenic fraction was 38.4%, with a range of 24.8-54.7%. These values are not different from the observed
gluconeogenic fraction in humans after a 14-h fast with the use of the
deuterated water method (6).
|
![]() |
DISCUSSION |
---|
![]() ![]() ![]() ![]() ![]() ![]() ![]() |
---|
Gluconeogenesis, defined as the conversion of nonglucose substrate to glucose, has been the subject of intensive research interest. Direct measurement of gluconeogenesis is possible but requires invasive catheterization to measure the balance of glucose and nonglucose substrates across the liver. Indirect methods to determine gluconeogenesis by use of tracers depend on the assumption of isotopic steady state and the models of tracer dilution before the final step of the combination of two triose phosphates.3 In the [U-13C6]glucose or [U-13C3]lactate method, possible sources of tracer dilution include dilution of lactate by other gluconeogenic substrates such as alanine and glutamate, dilution due to 13C exchange at the level of the TCA cycle, and dilution at the level of triose phosphate by glycerol. In the TCA cycle, the regeneration of oxaloacetate leads to significant exchange of 13C carbon with 12C of acetyl-CoA leading to the formation of m0, m1, m2, and m3 of PEP. It is generally agreed that the fraction of labeled lactate becoming m0 PEP by isotope exchange is small when the relative flux of pyruvate carboxylase to that of the citric acid cycle is >2 (3, 9). When the amount of m0 PEP generated is small, essentially every labeled molecule is recycled as a labeled molecule. Under such conditions, Landau et al. (7) argued that the gluconeogenic fraction can be calculated using Eq. 7 and no correction for the TCA cycle dilution is required. We have shown in our simulation that this argument is valid. Other methods to correct for TCA cycle dilution with (M1 + M2 + M3)/M3 as a dilution factor are valid only if m3 lactate is very much larger than the sum of m1 and m2 lactate (i.e., m1 + m2 is much smaller than 1 or 2% of m3 lactate). When m1 and m2 constitute >10% of the labeled lactate, M1 and M2 glucose can be formed from m1 and m2 lactate and the correction factor consistently overcorrects for the dilution and overestimates fractional gluconeogenesis, as pointed out by Landau et al.
Because the dilution at the level of triose phosphate by glycerol and pyruvate by gluconeogenic amino acids does not result in change of the distribution of mass isotopomers, dilution at these levels cannot be addressed by the [U-13C6]glucose method. The contribution of carbon from glycerol in the postabsorptive state is believed to be small (~3-5%) (8). It is difficult to estimate correctly the contribution of carbon from gluconeogenic amino acids because of extensive equilibration of isotope label and recycling of isotope. In our model, we assume that such processes contribute to the size of the lactate pool and that their effects can be minimized with [U-13C3]lactate priming.
Our simulation demonstrates that the distribution and the kinetics of the individual mass isotopomer are greatly affected by the compartment in which tracer is infused and the use of priming dose. Using the multicompartmental model of Landau et al. (7), we have shown by simulation that the appearance of M3 glucose follows that of a multiexponential equation (Eq. 3) when no isotope priming is used. Thus M3 glucose does not reach isotopic steady state even when M6 has reached its steady state, resulting in gross underestimation of gluconeogenesis. However, M3 glucose follows that of a single exponential when the lactate pool is primed with m3 lactate. This is understandable from the perspective of Eq. 3. When the priming dose is applied to a compartment, it is equivalent to setting the exponential term to its equilibrium value, which is zero. With successive priming of glucose and lactate, Eq. 3 is reduced to that of a single-exponential term.4 Our finding of the M3 glucose appearance curve to fit that of a single-exponential equation by SAAM analysis is consistent with the expected outcome of our simulation. Slow turnover compartments may exist that could alter the ultimate experimental M3 glucose plateau. The effect of fitting data to a single exponential when the model is actually a multiple-exponential (multicompartmental) structure is to underestimate the "true" plateau value. Longer infusion protocols are needed to determine whether the M3 appearance curve fits that of a single exponential out to experimental plateau, as predicted by our model. The advantage of using [U-13C3]lactate infusion can be visualized in the top curve of Fig. 3, where very little or no underestimation of fractional gluconeogenesis is achieved only when the addition of a primed constant infusion of [U-13C3]lactate is simulated. This approach needs further investigation.
The main question addressed by this study is whether delayed m3 lactate recycling contributes to underestimation in gluconeogenic fraction with the use of the primed constant infusion of [U-13C6]glucose. Without priming of the lactate compartment, [U-13C6]glucose carbon has to traverse two additional compartments before appearing as M3 glucose. The kinetic behavior of the M3 enrichment is best described by a multiexponential function. Thus the true plateau value can be missed if the rise in enrichment is slow toward the end of the infusion. We have shown that, when [U-13C3]lactate priming is used, the appearance of M3 glucose behaves like that of an exponential equation, as predicted by our simulation model. Furthermore, despite [U-13C3]lactate priming, M3 glucose enrichment did not reach plateau in the typical experimental time frame used by other investigators. If we assume that our model is correct, the modeling of the M3 glucose enrichment data using a curve-fitting program allows for the extrapolation of M3 enrichment to that of isotope steady state. We found that the plateau enrichment of the last time point was only 73-88% of the true plateau value as estimated using mathematical modeling with SAAM. Therefore, the lack of isotope equilibrium of the M3 glucose pool potentially contributed to 12-27% of the underestimation. The significance of the underestimation is also seen from the locations of the observed M3 being at the lower limits of the 95% confidence interval of the predicted values. In previous studies carried out without the primed constant infusion of lactate, this underestimation is expected to be even larger, because the m3 lactate compartment cannot reach its plateau value within the duration of the study. As demonstrated by simulation, without the additional infusion of labeled lactate, the underestimation of gluconeogenesis using the [U-13C6]glucose method is sufficiently large to account for the gross underestimation of gluconeogenesis in previous studies when the correct equations are applied.
![]() |
ACKNOWLEDGEMENTS |
---|
We are indebted to the nurses, dietary staff, and core laboratory technicians of the Clinical Study Center at Harbor-UCLA Medical Center for excellent assistance in the performance of these studies.
![]() |
FOOTNOTES |
---|
These studies were supported in part by a grant from the National Institutes of Health (NIH)-National Center for Research Resources (M01 RR-00425-27S8 to C. S. Mao) and the American Diabetes Association (to W.-N. P. Lee) and by a grant to the General Clinical Research Center at Harbor-UCLA Medical Center (NIH MO1-RR-00425).
Address for reprint requests and other correspondence: C. S. Mao, Harbor-UCLA Medical Center, 1000 W. Carson St., Torrance, CA 90509-2910 (E-mail: Mao{at}GCRC.REI.edu).
1 Many methods of correction for tracer dilution through the TCA cycle are based on the assumption of a single precursor species of labeled lactate (see review in Ref. 11). The presence of significant amounts of m2 and m1 lactate essentially invalidates this assumption. At present, the assumption of "no loss of labeled molecules" is probably the best approximation of the tracer dilution through the TCA cycle.
2
Equation 6 assumes that there is no
loss of labeled molecules via the TCA cycle. It is identical to the
equation for gluconeogenesis of Ref. 7. The factor 2 should be 2 × p × (1 p), where m3 + m2 + m1 is the enrichment of labeled lactate and (1
p) the unlabeled
lactate. The use of 2 instead of 2 × p × (1
p) is the source of the 2-5% underestimation; it can result in a larger underestimation when the enrichment of labeled lactate is higher (4).
3 The precursor enrichment is independently estimated in the combinatorial isotopomer analysis (MIDA) of Neese et al. (10).
4
Equation 3 has three exponential
terms; ya(t) = A0 A1 × exp(
a1 × t)
A2 × exp(
a2 × t)
A3 × exp(
a3 × t). At equilibrium, that is, when t for that term
is very large, A1 × exp(
a1 × t) approaches
zero. By successive priming, we are, in effect, increasing t
and reducing the importance of each term successively. A constant term
or a constant plus a single exponential can thus approximate Eq. 3.
The costs of publication of this article were defrayed in part by the payment of page charges. The article must therefore be hereby marked "advertisement" in accordance with 18 U.S.C. Section 1734 solely to indicate this fact.
10.1152/ajpendo.00210.2001
Received 14 May 2001; accepted in final form 16 October 2001.
![]() |
REFERENCES |
---|
![]() ![]() ![]() ![]() ![]() ![]() ![]() |
---|
1.
Genter, PM,
and
Ipp E.
Accuracy of plasma glucose measurements in the hypoglycemic range.
Diabetes Care
17:
595-598,
1994[Abstract].
2.
Haymond, MW,
and
Sunehag AL.
The reciprocal pool model for the measurement of gluconeogenesis by use of [U-13C]glucose.
Am J Physiol Endocrinol Metab
278:
E140-E145,
2000
3.
Katz, J,
Lee W-NP,
Wals P,
and
Bergner EA.
Studies of glycogen synthesis and the Krebs cycle by mass isotopomer analysis with [U-13C]glucose in rats.
J Biol Chem
264:
12994-3004,
1989
4.
Kelleher, JK.
Estimating gluconeogenesis with [U-13C]glucose: molecular condensation requires a molecular approach.
Am J Physiol Endocrinol Metab
277:
E395-E400,
1999
5.
Landau, BR.
Limitations in the use of [U-13C6]glucose to estimate gluconeogenesis.
Am J Physiol Endocrinol Metab
277:
E408-E413,
1999
6.
Landau, BR,
Wahren J,
Chandramouli V,
Schumann W,
Ekberg K,
and
Kalhan SC.
Contributions of gluconeogenesis to glucose production in the fasted state.
J Clin Invest
98:
378-385,
1996
7.
Landau, BR,
Wahren J,
Ekberg K,
Previs SF,
Yang D,
and
Brunengraber H.
Limitations in estimating gluconeogenesis and Cori cycling from mass isotopomer distributions using [U-13C6]glucose.
Am J Physiol Endocrinol Metab
274:
E954-E961,
1998
8.
Landau, BR,
Wahren J,
Previs SF,
Ekberg K,
Chandramouli V,
and
Brunengraber H.
Glycerol production and utilization in humans: site and quantitation.
Am J Physiol Endocrinol Metab
271:
E1110-E1117,
1996
9.
Lee, W-NP,
Sorou S,
and
Bergner EA.
Glucose isotope, carbon recycling, and gluconeogenesis using [U-13C]glucose and mass isotopomer analysis.
Biochem Med Metab Biol
45:
298-309,
1991[ISI][Medline].
10.
Neese, RA,
Schwarz JM,
Faix D,
Turner S,
Letscher A,
Vu D,
and
Hellerstein MK.
Gluconeogenesis and intrahepatic triose phosphate flux in response to fasting or substrate loads. Application of the mass isotopomer distribution analysis technique with testing of assumptions and potential problems.
J Biol Chem
270:
14452-14466,
1995
11.
Radziuk, J,
and
Lee W-NP.
Measurement of gluconeogenesis and mass isotopomer analysis based on [U-13C]glucose.
Am J Physiol Endocrinol Metab
277:
E199-E207,
1999
12.
Radziuk, J,
and
Lee W-NP.
[U-13C]glucose and the estimation of gluconeogenetic rates.
Am J Physiol Endocrinol Metab
277:
E414-E416,
1999
13.
SAAM Institute.
SAAM II User Guide. Seattle, WA: SAAM Institute, 1997, p. 115-168.
14.
Szafranek, J,
Pfaffenberger DC,
and
Horning EC.
The mass spectra of some per-O-acetylaldonitriles.
Carbohydr Res
38:
97-105,
1974[ISI][Medline].
15.
Tayek, JA,
and
Katz J.
Glucose production, recycling, and gluconeogenesis in normals and diabetics: a mass isotopomer [U-13C]glucose study.
Am J Physiol Endocrinol Metab
270:
E709-E717,
1996
16.
Tayek, JA,
and
Katz J.
Glucose production, recycling, Cori cycle, and gluconeogenesis in humans: relationship to serum cortisol.
Am J Physiol Endocrinol Metab
272:
E476-E484,
1997
17.
Tserng, KY,
Gilfillan CA,
and
Kalhan SC.
Determination of carbon-13 labeled lactate in blood by gas chromatography/mass spectrometry.
Anal Chem
56:
517-523,
1984[ISI][Medline].
18.
Yalow, RS,
and
Berson SA.
Immunoassay of endogenous plasma insulin in man.
J Clin Invest
39:
1157-1175,
1960[ISI].